No Picture
News

Inhibrx Strengthens Leadership Team with Three Key Executive Hires and Announces Appointment of Kristiina Vuori, M.D., Ph.D. to its Board of Directors

SAN DIEGO: SAN DIEGO, Oct. 28, 2021 /PRNewswire/ — Inhibrx, Inc. (Nasdaq: INBX), announced the appointment of three key executives: David Matly, M.B.A., as Chief Commercial Officer; David Kao, PharmD, M.B.A., RPh, as Vice President […]

No Picture
News

Synthekine Advances IL-2 Partial Agonist, STK-012, into Clinical Investigation for Treatment of Solid Tumors

MENLO PARK, Calif.–(BUSINESS WIRE)–Synthekine Inc., an engineered cytokine therapeutics company, today announced it is advancing its IL-2 partial agonist, STK-012, into clinical investigation following clearance of its investigational new drug (IND) application by the U.S. […]

No Picture
News

A pair of partners at Frazier is following early-stage biotechs to the public market with an $830M fund. And they’re already doing deals

Just a few days ago, the executive team at San Diego-based Crinetics $CRNX announced that it is spawning a newborn biotech which 5AM helped to create along with Frazier Healthcare Partners, helping it get launched […]

No Picture
News

Data from Phase 1/2a study of RM-1929 Photoimmunotherapy in Patients with Recurrent Head and Neck Squamous Cell Carcinoma was Published in Head and Neck

SAN MATEO, Calif.: SAN MATEO, Calif., Oct. 27, 2021 /PRNewswire/ — Rakuten Medical, Inc. (Rakuten Medical) announced that data from a phase 1/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head […]